DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA549128
Title:
Epigenetic Alterations Associated With CCCTC-Binding Factor Deregulation in Prostate Cancer
Descriptive Note:
Annual summary 30 Jun 2010-29 Jun 2011
Corporate Author:
WISCONSIN UNIV MADISON
Report Date:
2011-07-01
Pagination or Media Count:
10.0
Abstract:
CCCTC-binding factor CCTF is a widely expressed 11-zinc finger nuclear protein. CTCF plays an important role in epigenetic regulation by establishing, maintaining epigenetic states in the genome, preventing the spread of DNA methylation, and maintaining methylation-free zones important in gene transcription. CTCF regulates multiple genes involved in cell cycle progression and growth deregulation in both normal and prostate cancer cells. Thus, it serves as a master regulator that when functionally altered has the potential to globally change the behavior of a cell. It is our hypothesis that decreased CTCF expression in prostate cancer modulates the expression of growth promoting and tumor suppressor genes and may be an early permissive change in prostate cancer. Decreased CTCF expression would be associated with changes in local and global methylation especially at DNA binding sites of CTCF target genes in prostate cancer. Specific Aims 1 Determine if decreased expression of CTCF leads to the deregulation of growth regulatory genes in human prostate epithelial cells and prostate cancer cells. 2 To test if decreased expression of CTCF leads to changes in local and global methylation. 3 Determine CTCFBORIS expression or function in prostate cancer can predict clinical outcomes. To date, CTCF has not been examined in the context of prostate cancer and no studies have been done studying the effect of CTCF deregulation in normal or nontumorigenic cells. Given its role as a master regulator of multiple genes, this project has the potential to discover a new potential therapeutic target for future studies. Furthermore, CTCF could be used as a marker for prognostic and diagnostic purposes in prostate cancer.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
